Literature DB >> 25932142

Hypertensive vascular remodeling was inhibited by Xuezhikang through the regulation of Fibulin-3 and MMPs in spontaneously hypertensive rats.

Zhong-Wei Lin1, Zhuo Wang2, Gui-Ping Zhu3, Bo-Wei Li3, Wen-Lin Xie2, Ding-Cheng Xiang4.   

Abstract

Fibulin-3, an extracellular glycoprotein, has been suggested as having functions in vessels. In hypertension, extracellular matrix, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play important roles in cardiovascular remodeling. However, the role of Fibulin-3 as an extracellular glycoprotein in hypertensive vascular remodeling remains unclear. Our study was to determine whether Fibulin-3 and TIMPs/MMPs would affect vascular structure during hypertension and the treatment of Xuezhikang. Thirty spontaneously hypertensive rats (SHRs) aged 8 weeks were randomized to three groups: SHRs control group (SHRs group, n=10), group treated with low dose Xuezhikang (XZK-L, 20 mg/kg/d, n=10) and group treated with high dose Xuezhikang (XZK-H, 200 mg/kg/d, n=10), the normal group was comprised of ten Wistar-Kyoto (WKY) rats of the same age. We showed that serum nitric oxide (NO) in control group was significantly lower than WKY group (P<0.05). Concomitantly, serum oxidized low-density lipoprotein (ox-LDL) was higher than WKY group (P<0.05). The treatment of high dose Xuezhikang significantly dicreased ox-LDL, left ventricular mass index (LVMI) and Wall-to-lumen area ratio (W/L) of thoracic aorta (P<0.05), while serum NO was significantly increasing (P<0.05). Moreover, the expressions of Fibulin-3 and MMP-2, 9 at both protein and mRNA levels were significantly higher in thoracic aorta of SHRs group compared to WKY group by immunohistochemistry and western blotting (P<0.05). However, the levels of Fibulin-3 and MMP-2, 9 were significantly decreased in XZK-H group compared to control group (P<0.05). The level of TIMP-3 had no significance difference between SHRs and WKY groups (P>0.05). So the levels of Fibulin-3 and MMP-2, 9 in SHRs could be inhibited by Xuezhikang. Furthermore, a strong correlation in transcript expression was established between Fibulin-3, and MMP-2 (r=0.81, P<0.05) and MMP-9 (r=0.92, P<0.05) through immunohistochemistry. In summary, the overexpression of Fibulin-3 and MMP-2, 9 levels were associated with hypertension and vascular remodeling and inhibited by Xuezhikang. Fibulin-3 is a candidate in the pathogenesis of cardiovascular remodeling in hypertension.

Entities:  

Keywords:  Fibulin-3; hypertension; matrix metalloproteinase; spontaneously hypertensive rat; vascular remodeling

Year:  2015        PMID: 25932142      PMCID: PMC4402789     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  27 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

Review 2.  Extrinsic regulators of epithelial tumor progression: metalloproteinases.

Authors:  G Bergers; L M Coussens
Journal:  Curr Opin Genet Dev       Date:  2000-02       Impact factor: 5.578

3.  Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery.

Authors:  D P Mason; R D Kenagy; D Hasenstab; D F Bowen-Pope; R A Seifert; S Coats; S M Hawkins; A W Clowes
Journal:  Circ Res       Date:  1999 Dec 3-17       Impact factor: 17.367

4.  [Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].

Authors:  Fang-yong Jiang; Li-ping Sun; Jin Yang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2011-12

5.  Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease.

Authors:  Ling Liu; Shui-Ping Zhao; Yan-Chun Cheng; Yu-Ling Li
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

6.  The extracellular matrix and atherosclerosis.

Authors:  T N Wight
Journal:  Curr Opin Lipidol       Date:  1995-10       Impact factor: 4.776

7.  Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.

Authors:  M Aikawa; E Rabkin; Y Okada; S J Voglic; S K Clinton; C E Brinckerhoff; G K Sukhova; P Libby
Journal:  Circulation       Date:  1998-06-23       Impact factor: 29.690

8.  Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations.

Authors:  Philip A Klenotic; Francis L Munier; Lihua Y Marmorstein; Bela Anand-Apte
Journal:  J Biol Chem       Date:  2004-04-28       Impact factor: 5.157

9.  Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma.

Authors:  M Aikawa; E Rabkin; S J Voglic; H Shing; R Nagai; F J Schoen; P Libby
Journal:  Circ Res       Date:  1998-11-16       Impact factor: 17.367

10.  Plasma levels of the arterial wall protein fibulin-1 are associated with carotid-femoral pulse wave velocity: a cross-sectional study.

Authors:  Esben Laugesen; Pernille Høyem; Jens Sandahl Christiansen; Søren Tang Knudsen; Klavs Würgler Hansen; W Scott Argraves; Troels Krarup Hansen; Per Løgstrup Poulsen; Lars Melholt Rasmussen
Journal:  Cardiovasc Diabetol       Date:  2013-07-18       Impact factor: 9.951

View more
  2 in total

Review 1.  Traditional Chinese medicines in the management of cardiovascular diseases: a comprehensive systematic review.

Authors:  Kerry Layne; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2016-06-17       Impact factor: 4.335

2.  Fibulin-3 may improve vascular health through inhibition of MMP-2/9 and oxidative stress in spontaneously hypertensive rats.

Authors:  Zhongwei Lin; Zhuo Wang; Guobiao Li; Bowei Li; Wenlin Xie; Dingcheng Xiang
Journal:  Mol Med Rep       Date:  2016-03-21       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.